As part of our ongoing product review series, we have added a review of a medicine which has recently changed ownership and this provides a timely reminder to review a more recognised therapy option - Rosuvastatin calcium in patients with hypercholesterolaemia.
This review discusses evidence in support of the use of Rosuvastatin, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Associate Professor John Amerena, Cardiologist at Barwon Health and Director of the Geelong Cardiology Research Unit.
Please login below to download this issue (PDF)